Theravance Biopharma (NASDAQ:TBPH) Shares Cross Above 50 Day Moving Average – Here’s Why

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $9.38 and traded as high as $9.40. Theravance Biopharma shares last traded at $8.86, with a volume of 274,365 shares changing hands.

Theravance Biopharma Stock Performance

The stock’s fifty day moving average price is $9.38 and its 200-day moving average price is $8.90. The company has a market capitalization of $435.68 million, a P/E ratio of -8.77 and a beta of 0.21.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the transaction, the senior vice president now directly owns 309,565 shares of the company’s stock, valued at $2,786,085. This represents a 1.28 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TBPH. Newtyn Management LLC raised its holdings in Theravance Biopharma by 5.7% in the 4th quarter. Newtyn Management LLC now owns 4,757,403 shares of the biopharmaceutical company’s stock valued at $44,767,000 after acquiring an additional 258,337 shares during the period. BNP Paribas Financial Markets raised its holdings in Theravance Biopharma by 88.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company’s stock valued at $2,462,000 after acquiring an additional 143,781 shares during the period. Algert Global LLC bought a new position in Theravance Biopharma in the 3rd quarter valued at about $851,000. Dimensional Fund Advisors LP raised its holdings in Theravance Biopharma by 20.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company’s stock valued at $5,211,000 after acquiring an additional 95,304 shares during the period. Finally, Millennium Management LLC raised its holdings in Theravance Biopharma by 71.1% in the 4th quarter. Millennium Management LLC now owns 192,839 shares of the biopharmaceutical company’s stock valued at $1,815,000 after acquiring an additional 80,140 shares during the period. 99.10% of the stock is owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.